Global Breast Cancer Market 2027: Top Key Players Novartis AG, Genentech, Inc., GlaxoSmithKline plc, Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., AstraZeneca, Apotex Corp. Breckenridge Pharmaceutical, Inc., Pfizer Inc., Alvogen

Breast cancer start when cells in the breast begin to grow out of control. These cells form tumour that can often see on an x-ray. Breast cancer is the most common cancer among women, after skin cancer and second leading cause of cancer death in women after lung cancer. Breast cancer broadly classified into two include non-invasive and invasive breast cancer. Ductal carcinoma in situ (DCIS) is non-invasive cancer of milk duct cell. Invasive breast cancer divided into two types, invasive ductal carcinoma and invasive lobular carcinoma. Invasive ductal carcinoma also called infiltrating ductal carcinoma and it consist about 50-75 percent of all breast cancer. Invasive breast cancer that spread to other part of the body is called metastatic breast cancer. All non-invasive and invasive breast cancer tested for hormone (oestrogen and progesterone) receptors. The hormone receptor positive cancer can be treated with hormone therapy such as tamoxifen and aromatase inhibitor. Breast cancer is the most common cancer in women both in developed and developing countries. Breast cancer is most common in U.S. women with about 252,710 new case diagnosed and 40,610 die in 2017. Almost 81% of breast cancer are diagnosed among women age 50 year and older, and 89% of breast cancer deaths occur in this age group.

Request For Sample @ https://bit.ly/2C22hoq

Diagnosis of breast cancer can be done with physical examination, clinical breast examination (CBE), mammogram, ultrasound exam, MRI (magnetic resonance imaging), blood test and biopsy. Breast tissue biopsy include excisional biopsy, incisional biopsy, core biopsy and fine needle aspiration biopsy. There are different types of treatment for patients with breast cancer include surgery, chemotherapy, hormone therapy and targeted therapy. Surgery such as breast-conserving surgery, total mastectomy, modified radical mastectomy. Systemic chemotherapy is used in treatment of breast cancer include capecitabine (Xeloda), docetaxel (Taxotere), eribulin (Halaven), gemcitabine (Gemzar), paclitaxel (Taxol), vinorelbine (Navelbine) and others. Hormone therapy with a luteinizing hormone-releasing hormone (LHRH) agonist given to premenopausal who have diagnosed with hormone receptor positive breast cancer. Hormone therapy with an aromatase inhibitor include anastrozole, letrozole, and exemestane are given to postmenopausal women who have hormone positive breast cancer. Targeted therapy used in breast cancer include trastuzumab, pertuzumab, ado-trastuzumab emtansine, lapatinib, neratinib, palbociclib, ribociclib and abemaciclib.

The diagnosis, staging and treatment of patients with breast cancer require multidisciplinary care in acute hospital setting. In U.S. Genentech Access to Care Foundation (GATCF) scheme helping patients to have access to Herceptin. Genentech Access to Care Foundation (GATCF) scheme helps people who don’t have health insurance cover and those who have health insurance but have trouble paying for Herceptin. Additionally, Medicare insurance policies pays fee for a clinical breast examination (CBE) once every 2 years for women at average risk of breast cancer.

Request For Table Of Content (TOC) @ https://bit.ly/2C22hoq

Key players operating breast cancer market are Novartis AG, Genentech, Inc., GlaxoSmithKline plc, Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., AstraZeneca, Apotex Corp. Breckenridge Pharmaceutical, Inc., Pfizer Inc., Alvogen and others

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products.

Contact Us:
Mr. John Smith
InsightAce Analytic Pvt. Ltd.
Pune, Maharashtra, India
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: https://www.insightaceanalytic.com
Follow Us on LinkedIn @ https://bit.ly/2tBXsgS
Follow Us On Facebook @ https://bit.ly/2H9jnDZ

This release was published on openPR.